GlassScriptPhysician profile
Pratik Patel
NPI 1952321077
$15,528.00
in general payments reported to CMS, 2019-2025
49 companies · $6,487 in 2025
The $6,487 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $740 · 2021: $700 · 2022: $1,388 · 2023: $2,243 · 2024: $2,428 · 2025: $6,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,000 · Education: $4,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,999.80 |
| Education | $4,158.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,375.65 | 2019-2025 | |
| Boston Scientific Corporation | $2,140.04 | 2020-2025 | Avvigo Guidance System, Comet, Mamba |
| Actelion Pharmaceuticals US, INC. | $1,233.09 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $1,219.20 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.39 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Astellas Pharma US INC | $617.91 | 2023-2025 | Cresemba, Izervay |
| Astrazeneca Pharmaceuticals LP | $504.30 | 2019-2025 | Fasenra, Tezspire, Breztri |
| United Therapeutics Corporation | $497.11 | 2022-2025 | Tyvaso, Orenitram, Tyvaso |
| Genzyme Corporation | $393.88 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.24 | 2020-2025 | Glassia, Livtencity, Aralast |
| Abbott Laboratories | $257.39 | 2019-2025 | Amplatzer Amulet, Esprit |
| Mylan Specialty L.P. | $220.18 | 2022-2024 | Yupelri |
| Pulmonx Corporation | $218.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $208.00 | 2020-2025 | Winrevair, Keytruda |
| Insmed, INC. | $207.64 | 2019-2025 | Arikayce, Brinsupri |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $179.80 | 2019 | |
| Ethicon INC. | $168.94 | 2019 | |
| Abbvie INC. | $161.89 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $122.19 | 2020-2023 | Xarelto |
| Viatris Specialty LLC | $117.18 | 2025 | Yupelri |
| Amgen INC. | $105.90 | 2019-2024 | Tezspire, Tavneos |
| Ambu INC. | $96.10 | 2020 | |
| Genentech USA, INC. | $95.82 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $93.51 | 2023-2025 | Purified Cortrophin Gel |
| Eurofins Viracor, LLC | $86.69 | 2024 | |
| Inari Medical, INC. | $74.39 | 2020 | |
| Abiomed | $69.11 | 2024 | Impella |
| Vifor Pharma, INC. | $68.00 | 2024-2025 | Zemaira |
| Cmp Pharma, INC. | $66.91 | 2023 | Tadliq, Norliqva, Liqrev |
| Allergan, INC. | $66.06 | 2019-2020 | |
| Amarin Pharma, INC. | $56.96 | 2020-2021 | |
| Shire North American Group INC | $56.53 | 2019 | |
| Cardiva Medical, INC. | $45.12 | 2022 | |
| Novo Nordisk INC | $33.48 | 2024 | Wegovy |
| Kamada LTD. | $32.93 | 2025 | |
| Mallinckrodt Hospital Products INC. | $31.42 | 2022-2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $30.99 | 2022-2024 | Dupixent |
| 3b Medical, INC. | $30.81 | 2024 | Luna |
| Pfizer INC. | $30.00 | 2019-2020 | |
| Harmony Biosciences LLC | $29.18 | 2022 | |
| Csl Behring | $27.30 | 2020 | |
| Gilead Sciences, INC. | $26.71 | 2019 | |
| La Jolla Pharmaceutical Company | $24.01 | 2023 | Giapreza |
| Novartis Pharmaceuticals Corporation | $19.21 | 2025 | |
| Covidien LP | $16.50 | 2020 | |
| Pharming Healthcare, INC. | $16.00 | 2023 | Ruconest |
| Mallinckrodt Enterprises LLC | $15.00 | 2019 | |
| Daiichi Sankyo INC. | $15.00 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.